Revive Therapeutics and PharmaTher are teaming up to research the potential of psilocybin as a cancer treatment.
Psychedelics
Field Trip Health Ltd. and WHOOP announce partnership to measure effect of psychedelic therapies on physiology and mental health
Field Trip announces a new clinics-based research program, beginning with psychedelic therapies for military veterans.
Mind Cure Announces Closing of Oversubscribed $3.6 Million Offering
Including its new financing, Mind Cure currently has in excess of CAD$5 million in cash.
Delic Corp Commences Trading On CSE
Delic Corp is a Delaware-based psychedelics company that has gone public via RTO.
Psychedelic Drug Therapy: Cure Your Mind, Save Your Heart?
Will psychedelic drug therapies (simultaneously) save lives as they cure mental health disorders?
Numinus Announces Compassionate Access Trial of Psilocybin-Assisted Psychotherapy for Substance Use Disorders
Numinus plans a "compassionate access" clinical trial of psilocybin to treat substance abuse.
Mind Cure Science Advisor Becomes First CSO As It Builds World-Class Team
Mind Cure's new CSO is a decorated researcher, entrepreneur and inventor.
Mydecine Innovations Group Offers Management and Clinical Trials Update
Mydecine provides an update on its Phase 2A clinical trial of psilocybin-assisted psychotherapy for the treatment of PTSD.
Field Trip Health Ltd. Announces Expansion to The Netherlands and Launch of Proprietary Truffle Program
Field Trip is entering the (already legal) Netherlands psilocybin market with a "Field Trip Health Center" in Amsterdam.
More U.S. Military Funding For Psychedelic Drug R&D As PTSD Crisis Worsens
To commercialize psychedelic drugs, they first have to be legalized. In the United States, an important ally in this battle has surfaced: the DoD.
MindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial from Swiss and Dutch Health Authorities
Another incremental step forward in one of MindMed's leading psychedelics R&D initiatives.
Mind Cure Announces Non-Brokered Private Placement of up to $3 Million
Mind Cure Health is seeking to raise $3 million via the sale of 6.66 million units.
A Market Reality Check For Psychedelic Stocks
The Psychedelics Revolution is here to stay. The solutions of tomorrow are the investments of today.
Navy SEAL Foundation Contributes $50,000 to Support Major PTSD Study
The Navy SEAL Foundation (NSF) recently pledged one of the organization’s largest single grants in its 20-year history to support a major Post Traumatic Stress Disorder (PTSD) study.
Mind Cure Announces Hiring of Award-Winning Experimental Scientist Dr. Ryan Hartwell as Chief Science Officer
Mind Cure's new Chief Science Officer (CSO) brings experience in drug research as well as natural product development.